RT Journal Article
SR Electronic
T1 No difference in retinal fluorescence after oral curcumin intake in amyloid proven AD cases compared to controls
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.07.21264420
DO 10.1101/2021.10.07.21264420
A1 den Haan, Jurre
A1 Hart de Ruyter, Frederique J.
A1 Lochocki, Benjamin
A1 Kroon, Maurice A.G.M.
A1 Kemper, E. Marleen
A1 Teunissen, Charlotte E.
A1 van Berckel, Bart
A1 Scheltens, Philip
A1 Hoozemans, Jeroen J.
A1 van de Kreeke, Aleid
A1 Verbraak, Frank D.
A1 de Boer, Johannes F.
A1 Bouwman, Femke H.
YR 2022
UL http://medrxiv.org/content/early/2022/08/17/2021.10.07.21264420.abstract
AB INTRODUCTION Previous work showed the in-vivo presence of retinal amyloid in AD patients using curcumin. We aimed to replicate these findings in an amyloid biomarker confirmed cohort.METHODS Twenty-six AD patients (age 66 (+9), MMSE≥17) and 14 controls (age 71(+12)) used one of three curcumin formulations: Longvida®, Theracurmin® and Novasol®.Plasma levels were determined and pre- and post-curcumin retinal fluorescence scans were visually assessed in all cases and quantitatively assessed in a subset.RESULTS Visual assessment showed no difference between AD patients and controls for pre- and post-curcumin images. This was confirmed by quantitative analyses on a subset. Mean conjugated plasma curcumin levels were 198.7 nM (Longvida®), 576.6 nM (Theracurmin®) and 1605.8 nM (Novasol®).DISCUSSION We found no difference in retinal fluorescence betweenamyloid confirmed AD cases and control participants, using Longvida® and two additional curcumin formulations. Additional replication studies in amyloid confirmed cohorts are needed to assess the diagnostic value of retinal fluorescence as an AD biomarker.Competing Interest StatementResearch of CT is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. CT has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. FB has a collaboration contract with Biogen, Optina Dx and Roche. Payments are made to the institution of VUMC. FB is committee member of EAN and chairs the atypical AD PIA and the Eye as biomarker for AD PIA of ISTAART. PS is chair steering committee in NOVARTIS, member DSMB GENENTECH, global PI phase s! study AC IMMUNE, member advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX and CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global phase 2B study Vivoryon, PI global phase 2A study TOYAMA / FUJI FILM, PI global phase 1A study IONIS, personal fees from Life Science Partners Amsterdam, outside the submitted work. JB is supported for the current study by NWO (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and Co-financing by Heidelberg engineering as part of the competitive research proposal, administered by the funding agency. Both these fundings are paid to institution. Besides this study JB received past 36 months research grants from Heidelberg, TKI, TNO, LSHM paid to institution. Personal fees from royalties through former employer, Massachussets general Hospital, for IP that has been licensed to Terumo, Heidelberg engineering and Spectrawave as well as fees for expert witness for a UK based law firm. He is program committee member for a number of conferences, unpaid. JdH, FH, MK, MK, BB, JH, AK, FV report no conflict of interestClinical TrialnaFunding StatementWe gratefully acknowledge financial support from Stichting Alzheimercentrum VUMC, Alzheimer Nederland, the Dutch Technology Foundation STW (grant number 13935), part of the Netherlands Organization for Scientific Research (NWO), and which is partly funded by the Ministry of Economic Affairs, ISAO (grant number 14518).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was designed and conducted according to the Declaration of Helsinki and the study protocol was approved by the Ethical Committee of the VU University Medical Center. All patientsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon reasonable request